IP Library Granted Patent US 8,524,006
Granted Patent B2
US 8,524,006 · App. 13/446,008 · Granted Sep 3, 2013

Target bodies and uses thereof in the production of radioisotope materials

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,006
App. No.
13/446,008
Granted
Sep 3, 2013
Kind
B2
Abstract

A system and method are provided for reclaiming an enriched radioisotope starting material from a target body. The system and method enable reclaiming the starting material in a relatively short time (e.g., several hours) after the target body's bombardment with energetic particles, greatly simplifying the target body's chemical processing, as well as reducing the cost of such processing (e.g., reducing the need for costly long-term storage). Specifically, a chemical protective layer is disposed between a radioisotope starting material and a base material of the target body. After the target body is irradiated with a suitable source (e.g., particle accelerator), then the irradiated radioisotope starting material can be removed without removing the base material due to the protection provided by the chemical protective layer. The system and method also enable the operator to obtain three different radioisotopes in a single bombardment of the target body, further reducing cost of radioisotope production.

Claims (24)

1. A method for removing a material from an irradiated target body, comprising:

stripping a first layer comprising thallium 203 from the target body using nitric acid to form a solution; and

reducing removal of a second layer of the target body using a protective layer resistant to removal by nitric acid, wherein the protective layer includes chromium and is located between the first layer and the second layer prior to the stripping.

2. The method of claim 1 , further comprising chemically stripping the protective layer comprising a second radioisotope material from the irradiated target body after chemically stripping the first layer.

3. The method of claim 2 , comprising chemically stripping the second layer comprising a radioisotope material from the irradiated target body after chemically stripping the first layer and after chemically stripping the protective layer.

4. The method of claim 3 , wherein the second layer comprises a base of the target body.

5. The method of claim 1 , comprising chemically separating the lead 201 material from a remaining portion of the solution.

6. The method of claim 5 , comprising reclaiming the remaining portion for additional radioisotope generation within less than a week.

7. The method of claim 5 , comprising reclaiming the remaining portion for additional radioisotope generation within less than several hourc, one day.

8. The method of claim 5 , wherein the remaining portion comprises enriched thallium 203.

9. The method of claim 1 , wherein the second layer comprises copper.

10. A method for removing a material from an irradiated target body, comprising:

chemically stripping a first layer comprising a first radioisotope material and starting material selected from the group comprising cadmium 112, zinc 68, thallium 203 or a combination thereof from the target body;

reducing removal of a second layer of the target body using a protective layer of the target body, wherein the protective layer is located between the first layer and the second layer prior to the chemically stripping; and

chemically separating the first radioisotope material from a remaining portion of the first layer.

11. The method of claim 10 , wherein the protective layer resists chemicals used for chemically stripping the first layer.

12. The method of claim 10 , wherein the chemical used for stripping the first layer is hot nitric acid.

13. The method of claim 10 , further comprising chemically stripping the protective layer comprising a second radioisotope material from the irradiated target body after chemically stripping the first layer.

14. The method of claim 13 , comprising chemically stripping the second layer comprising a radioisotope material from the irradiated target body after chemically stripping the first layer and after chemically stripping the protective layer.

15. The method of claim 14 , wherein the second layer comprises a base of the target body.

16. The method of claim 10 , comprising reclaiming the remaining portion for additional radioisotope generation within less than a week.

17. The method of claim 10 , comprising reclaiming the remaining portion for additional radioisotope generation possible within less than a day.

18. The method of claim 10 , wherein the first radioisotope material comprises lead 201 and the remaining portion comprises enriched thallium 203.

19. The method of claim 10 , wherein the first layer comprises thallium 203, the second layer comprises copper, and the protective layer comprises chromium.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →